𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease

✍ Scribed by L. Priano; G. Albani; S. Calderoni; S. Baudo; L. Lopiano; M. Rizzone; V. Astolfi; R. Cavalli; M.R. Gasco; F. Fraschini; B. Bergamasco; A. Mauro

Book ID
106269724
Publisher
Springer Milan
Year
2002
Tongue
English
Weight
35 KB
Volume
23
Category
Article
ISSN
1590-1874

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Transdermal apomorphine permeation from
Transdermal apomorphine permeation from microemulsions: A new treatment in Parkinson's disease
✍ Lorenzo Priano; Gianni Albani; Andrea Brioschi; Sara Calderoni; Leonardo Lopiano πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 75 KB

## Abstract We studied absorption, efficacy, and tolerability in Parkinson's disease (PD) of a new preparation of apomorphine included in a microemulsion and administered by transdermal route (Apo‐MTD). Twenty‐one PD patients were treated with levodopa plus oral dopamine‐agonists (T0), with levodop

A novel sublingual apomorphine treatment
A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease
✍ William Ondo; Christine Hunter; Michael Almaguer; Joseph Jankovic πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 60 KB πŸ‘ 2 views

We tested a novel preparation of a sublingual apomorphine hydrochloride tablet (APO) in 10 patients with advanced Parkinson's disease complicated by motor fluctuations. After a dose titration, patients took either 40 mg APO three times per day alternating with levodopa doses (eight patients) or six

Early treatment benefits of ropinirole p
Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations
✍ Bonnie P. Hersh; Nancy L. Earl; Robert A. Hauser; Mark Stacy πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 488 KB πŸ‘ 1 views

A correct balance between endocannabinoid and dopamine-dependent systems is believed to underlie physiological motor control. We measured the levels of the endocannabinoid anandamide in the cerebrospinal fluid of Parkinson's disease (PD) patients. Subjects were divided into three groups: newly diagn